JP2006514024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514024A5 JP2006514024A5 JP2004561407A JP2004561407A JP2006514024A5 JP 2006514024 A5 JP2006514024 A5 JP 2006514024A5 JP 2004561407 A JP2004561407 A JP 2004561407A JP 2004561407 A JP2004561407 A JP 2004561407A JP 2006514024 A5 JP2006514024 A5 JP 2006514024A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- seq
- nkp30
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43534402P | 2002-12-23 | 2002-12-23 | |
| PCT/EP2003/014716 WO2004056392A1 (en) | 2002-12-23 | 2003-12-22 | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514024A JP2006514024A (ja) | 2006-04-27 |
| JP2006514024A5 true JP2006514024A5 (enExample) | 2007-02-08 |
Family
ID=32682222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004561407A Pending JP2006514024A (ja) | 2002-12-23 | 2003-12-22 | Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080063717A1 (enExample) |
| EP (1) | EP1575615A1 (enExample) |
| JP (1) | JP2006514024A (enExample) |
| AU (1) | AU2003294930B2 (enExample) |
| CA (1) | CA2510787A1 (enExample) |
| WO (1) | WO2004056392A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| EP2292264A3 (en) * | 2003-07-24 | 2012-12-19 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| US20070178106A1 (en) * | 2004-04-30 | 2007-08-02 | Innate Pharma, S.A. | Compositions and methods for enhancing nk cell activity |
| WO2006072625A2 (en) * | 2005-01-06 | 2006-07-13 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| AU2006340750B2 (en) | 2005-11-28 | 2013-03-07 | Zymogenetics, Inc. | IL-21 antagonists |
| EP2217268B1 (en) | 2007-12-07 | 2016-05-04 | ZymoGenetics, Inc. | Anti-human il-21 monoclonal antibodies |
| KR101133185B1 (ko) * | 2008-07-29 | 2012-04-06 | 서울대학교병원 | 자연살해세포의 증식방법 |
| TWI560200B (en) | 2011-05-25 | 2016-12-01 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
| JP5572863B2 (ja) * | 2011-06-24 | 2014-08-20 | 国立大学法人九州大学 | Ｎｋ細胞の増幅方法 |
| DE14740451T1 (de) | 2013-01-15 | 2016-03-31 | Hiroyuki Abe | Verfahren zur Herstellung einer immunozytenhaltigen Zusammensetzung und Zusammenstzung zur Behandlung von Krebs |
| EP2824112B1 (en) | 2013-07-10 | 2016-12-21 | Miltenyi Biotec GmbH | Method for inducing proliferation of Natural Killer cells by mobile nanomatrices |
| CN105462923B (zh) * | 2014-12-17 | 2018-11-02 | 山东大学第二医院 | 一种人自然杀伤细胞体外高效扩增方法 |
| JP6073417B2 (ja) * | 2015-06-26 | 2017-02-01 | チャ バイオテック カンパニー リミテッド | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| CN115925933A (zh) * | 2015-12-28 | 2023-04-07 | 依奈特制药公司 | NKp46结合蛋白的可变区 |
| CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US20210290672A1 (en) * | 2016-08-17 | 2021-09-23 | University Health Network | Regulation of tumor-associated t cells |
| IL322309A (en) | 2017-05-24 | 2025-09-01 | Novartis Ag | IL2 antibody grafted proteins and methods of use in cancer treatment |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020135518A1 (en) * | 2018-12-25 | 2020-07-02 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric il15 |
| EP3927744A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| GB2597851B (en) * | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| WO2021143858A1 (en) * | 2020-01-17 | 2021-07-22 | Beigene, Ltd. | ANTI-NKp30 ANTIBODIES AND METHODS OF USE |
| CA3180321A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| JP2023540248A (ja) | 2020-08-26 | 2023-09-22 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法 |
| WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
| KR102581230B1 (ko) * | 2020-10-16 | 2023-09-21 | 의료법인 성광의료재단 | 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도 |
| KR102236011B1 (ko) * | 2020-11-11 | 2021-04-05 | 한바이오 주식회사 | Nk 세포의 대량증식 배양방법 |
| AU2022389974A1 (en) | 2021-11-19 | 2024-06-20 | Sundance Spas, Inc. | Self-maintaining hot tub or spa |
| WO2025019077A1 (en) | 2023-07-18 | 2025-01-23 | Nanotein Technologies, Inc. | Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60041655D1 (de) * | 1999-11-15 | 2009-04-09 | Innate Pharma | Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren |
| US6979546B2 (en) * | 1999-11-15 | 2005-12-27 | Universita Di Genova | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
-
2003
- 2003-12-22 AU AU2003294930A patent/AU2003294930B2/en not_active Ceased
- 2003-12-22 WO PCT/EP2003/014716 patent/WO2004056392A1/en not_active Ceased
- 2003-12-22 EP EP03785910A patent/EP1575615A1/en not_active Withdrawn
- 2003-12-22 US US10/539,828 patent/US20080063717A1/en not_active Abandoned
- 2003-12-22 JP JP2004561407A patent/JP2006514024A/ja active Pending
- 2003-12-22 CA CA002510787A patent/CA2510787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514024A5 (enExample) | ||
| KR101092132B1 (ko) | 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법 | |
| JP2021184721A5 (enExample) | ||
| Curnow | Clinical experience with CD64-directed immunotherapy. An overview | |
| CA2261630C (en) | Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease | |
| JP6215429B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| KR101733252B1 (ko) | Ｃｄ３８을 특이적으로 인식하는 항체 및 멜팔란을 함유하는 항종양 조합물 | |
| US8623837B2 (en) | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| US20210061911A1 (en) | Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies | |
| DE69830570T2 (de) | Immuntherapie der b-zell bösartige krankheiten mittels anti-cd22 antikörper | |
| JP2009541492A5 (enExample) | ||
| JP2010540616A5 (enExample) | ||
| AU2005215874B2 (en) | Anti-EpCAM immunoglobulins | |
| JP2019513013A5 (enExample) | ||
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| WO2019089870A1 (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| US20240009275A1 (en) | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment | |
| Wu et al. | Trastuzumab therapies in human epidermal growth factor receptor 2 cancer | |
| CN117357637A (zh) | 一种治疗肿瘤的联合用药物组合物及其用途 | |
| Kato | Moxetumomab pasudotox | |
| JPWO2022232558A5 (enExample) | ||
| HK1177144A (en) | Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor | |
| HK1047043B (en) | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody | |
| HK1140697A (en) | Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor |